ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

TRENDS IN FINANCIAL PERFORMANCE AND MARKET CAPITALIZATION OF BIOPHARMACEUTICAL COMPANIES: A LONGITUDINAL STUDY

Dr. ShivaniBector
Designation - Assistant Professor
Department - Management Studies
University -Mata Gujri College, Fatehgarh Sahib
Email - shivanimgc@gmail.com

ABSTRACT

This longitudinal study delves into the trends in financial performance and market capitalization of the biopharmaceutical companies over a substantial period. The biopharmaceutical sector, renowned for its critical contributions to healthcare advancements, has been experiencing significant growth and transformations in recent years. Understanding the financial aspects of these companies is vital for investors, policymakers, and stakeholders to make informed decisions. The research leverages comprehensive data from diverse biopharmaceutical firms spanning multiple years to thoroughly analyze their financial performance. Key financial indicators, such as revenue growth, profitability, liquidity, and solvency, are meticulously examined to discern patterns and shifts in the industry's financial landscape.

Furthermore, the study scrutinizes the biopharmaceutical companies' market capitalization fluctuations. Market capitalization, a reflection of investor sentiment and market valuation, is a crucial metric in gauging the industry's overall health and potential for growth. The findings of this research paper shed light on the significant drivers behind the financial performance and market capitalization trends in the biopharmaceutical sector. Additionally, it identifies potential correlations between financial performance and market capitalization, offering insights into the factors that influence investor perceptions and decisions. In conclusion, this study provides a comprehensive and up-to-date overview of the biopharmaceutical industry's financial landscape. It enables stakeholders to understand its dynamics better and make informed choices in an ever-evolving market. The research offers valuable implications for investors, executives, and policymakers aiming to capitalize on the opportunities presented by the biopharmaceutical sector's growth and potential.

Keywords: Financial performance, profitability measures, growth measures, market capitalization.

I. INTRODUCTION

The ability to promote innovation-based sectors is seen as crucial to the economic competitiveness of our country. The capacity to innovate is the single most significant factor in a country's economic development and its ability to compete and succeed in the global economy of the twenty-first century, according to the National Research Council (NRC).1 Aside from significantly expanding the national economy, novel ideas also help set individual states and regions apart. According to the data collected for this research, the biopharmaceutical business is a substantial source of employment in several areas while providing jobs to residents of all 50 states, the District of Columbia, and Puerto Rico. Substantial evidence shows that innovation is critical to economic

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

expansion and improving living conditions. State innovation capabilities are positively correlated with per capita income, as measured by the State New Economy Index created by the Information Technology and Innovation Foundation.

In recent years, the general public and the scientific community have been more interested in and concerned about the planet's sustainable development, as shown in efforts like the objectives stated in the 2030 Agenda for Sustainable Development [1]. "From green bond issuance [2] to evaluating business strategies [3] to the design of initiatives in different territories, social and economic actors have tried to offer new answers and solutions to contribute to achieving these relevant goals." One example is the nature-based solutions promoted by the European Commission. Unfortunately, various harmful impacts, such as climate change, have been formed on the planet as a result of the endless increase of the population and the development of the economy based on the heavy use of limited resources, with terrible repercussions for human life. Due to human interference, natural catastrophes have become more common, and new infectious illnesses have emerged.

A. Defining the Biopharmaceutical Industry

The firms that make up the biopharmaceutical sector and the connections between them are constantly evolving. Industry participants include, but are not limited to, large, vertically integrated biopharmaceutical corporations with their own research and manufacturing facilities; small and startup corporations without an FDA-approved medicine; clinical development and management and research organizations offering a variety of services to support drug development and manufacturing; and distributors offering logistical support to deliver prescribing physicians' orders. Companies in the biopharmaceutical industry work together in a wide range of partnerships to promote research and create cutting-edge medicines, just as they do with academia and other public and private organizations. "For instance, a biopharmaceutical firm may license technology from another firm or an academic medical researcher, such as a novel assay or a promising compound, to advance a specific technology or medicine in development through a clinical trial". Companies in the biopharmaceutical industry often have their own corporate venture capital divisions that will invest in new businesses at any level of development, including those working on innovative digital health applications. Estimates of the size and structure of the U.S. biopharmaceutical industry were generated using the industry's core activities, which remain uncomplicated despite the industry's growth and diversification: biopharmaceutical discovery, research, development, manufacturing, and distribution. "Threesectorsof the United States economy, as defined by the government in the North American Industrial Classification System (NAICS), include all or a portion of these pursuits." Corporate headquarters in the biopharmaceutical industry is a separate sector that accounts for the industry's administrative functions. The estimates were derived by painstakingly isolating the biopharmaceutical sector's contribution to the various economic sectors.

II. LITERATURE REVIEW

Sustainability has become essential to national and international economic development in response to individuals' rising fears and concerns about environmental preservation and care for the earth. The Global Hazards Perception Survey [4] is one indicator of this growing awareness; for the first time in its history, environmental hazards were ranked among the top five perceived concerns for the next decade in 2019. Extreme weather, failure to take action on climate change, human environmental harm, and biodiversity loss all remained in the top five environmental threats in the 2020 study, with infectious illnesses moving up to fourth place. These environmental dangers are all connected to human activity but in various ways. Human activities

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

are identified as a major contributor to significant biophysical changes in earth systems that have far-reaching consequences for human health and well-being by proponents of the planetary health concept. “Multiple scientists agree that these shifts mark the beginning of a new geological era called the Anthropocene, which is defined by negative human impacts on the planet [5] and manifested in six dimensions: climate change; global air, water, and soil pollution; biodiversity loss; altered biogeochemical cycles; changes in land use and land cover; and resource scarcity, especially freshwater and arable land.” As a result of these shifts, more people will be vulnerable to infectious illnesses and other natural disasters such as heat waves, floods, droughts, fires, and tropical storms [6]. According to this, the fundamental worry is that the existing style of existence will not be sustainable due to unchecked economic expansion and a lack of knowledge of the relationship between people and the environment.

Human and economic activity outcomes have negatively impacted numerous regions, markets, and fields, and this trend is only expected to increase. Climate change, one of the significant human-induced effects due to the accumulation of greenhouse gases in the atmosphere, now poses a significant risk to human health [7]. In recent years, hurricanes, floods, droughts, wildfires, heat waves, and even disease outbreaks have all been linked to climate change. Climate change has become more evident via the increasing frequency and intensity of these occurrences and the extraordinary consequences it has had on human welfare and health and the availability of freshwater, one of our most valuable commodities [8]. The aim of providing everyone with safe, reliable, and inexpensive water is more distant. Increases in energy use and agricultural product demand are only two outcomes of inadequate water resource management in the face of persistent population and economic expansion. The interdependence of water, energy, and agriculture is particularly vulnerable [9] because changes or poor practices in any of these sectors may have far-reaching consequences for others and, by extension, human and planetary health.

There is a 'paradoxical cycle' that humanity has entered, whereby human activities generate changes and harm in one system or sector, affecting other systems or sectors, with unknown outcomes for humanity. Therefore, global warming can cause an increase in energy demand (a potential source of greenhouse gas emissions), which in turn increases the need for water resources to produce energy that is no longer used in other companies, such as agriculture or food, which may result in significant resource management imbalances between these sectors. Because of the intricate web of interdependencies among companies, tracing the origins of any given chain of events may be a herculean task, and sometimes the end result might need to be revised. Therefore, urgent cooperative multistakeholder efforts are needed to build sustainable management and production models that can fulfill socioeconomic needs while protecting resources for future generations due to human-induced imbalances in many companies and sectors. The EU's Nature-Based Solutions are one example of an initiative that aims to promote biodiversity conservation, natural disaster reduction, the development of circular economy and energy efficiency models, and resilience to climate change [10]. “Governments, organizations, and all of society must work towards a greener and more sustainable economy by offering innovative solutions to promote the efficient use of natural resources.”

The recent COVID-19 epidemic highlights the importance of healthcare development and delivery to the health and wellness of all economic agents and the economy's running. The market capitalization of U.S. biotechnology (biotech) and pharmaceutical (pharma) companies has increased over time (Figure 1), as has the amount invested by both companies in biomedical R&D.Healthcare expenditure in the United States is expected to reach $6.2 trillion by 2028, growing steadily both in absolute terms and as a share of GDP.1 A growing body

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

of work, however, has demonstrated severe underinvestment compared to the societal optimum in the research and development required to manufacture healthcare medicines (for a summary, see [11]). A persistent "funding gap" in research and development (e.g., [12–26]) contributes to this underinvestment. The extended period, high financial needs, and technical difficulties of drug development are only some of the reasons why this funding gap is especially acute for biomedical R&D [12]. Less money will be spent on research and development, meaning fewer potentially life-saving treatments for patients.

The cost of producing a single medicine is substantial, and there is evidence to imply that this cost has been rising over time [17]. Since businesses without FDA-approved drugs have no income, the significant development expenses suggest that biopharma enterprises require substantial external finance [18]. In keeping with the more general known relationship between stock markets and R&D spending by corporations [19], biopharma companies depend extensively on external equity funding (e.g., [11]). IPOs are a common way for tiny biotech companies with merely preclinical assets to get access to public stock markets [20]. Due to their negative cash flows and lack of physical assets that can be used as security, debt financing is often less appealing for biotech enterprises. However, debt financing may be feasible in particular instances, which we will explain later.

Regarding external finance frictions, biopharma companies face an amplified version of such challenges because of the institutional aspects of drug development. For instance, the low odds of ultimate success (i.e., FDA approval) and the highly technical and specialized character of the drug development process might increase asymmetric knowledge, which leads to unfavorable selection costs [21]. "Liu [22] uses project-level data on biotech startups to build a dynamic structural model and shows that information-induced financing frictions lead to a loss of around 24% in company value." Because of these factors in pharmacological research, moral hazard might emerge and be hard to rein in [18]. The fact that many of the assets created during medication research cannot be pledged to lenders makes the situation much more precarious. Although non-pledgeability is also seen in other settings [23], it presents a far more significant problem for biopharma companies. Consider Eli Lilly's purchase of Hybritech in 1986 to understand why this is the case. Hybritech's monoclonal antibody (MoAb) research for cancer treatment was the company's most significant asset, while its diagnostic equipment assets constituted a far lower part of its total worth. Hybritech had difficulty getting debt financing because Eli Lilly needed help valuing the MoAb research assets the company was pledging as collateral.

III. HYPOTHESES OFTHESTUDY

H01: Net profit ratioduringthe processand productpatentperiods isnotsignificantlydifferentduring the processand productpatentperiods.

H02: ReturnonTotalAssetsduring the processpatentperiodisnotsignificantlydifferentfromReturnonTotalAssetsduringtheproductpatentperiod.

H03: Thereis no significantdifferenceinreturn on capitalemployedduring processandproductpatentperiods.

H04: Nosignificantdifferenceisfoundforreturnonnetworthduringthe process and product patentperiods.

H05: Nosignificantdivergenceisfoundforthe Total assets growthduringprocessandproductpatentperiods.

H06: The total sales growthduringthe processpatentperiodandtheproductpatentperiodissimilar.

H07: Thereisnoconsiderabledifferenceinthe market capitalization growthduringprocess and

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

productpatentperiods.

IV. RESEARCHMETHODOLOGY

The following methodology has been adopted to achieve the hypotheses mentioned above. Financialstatementsandvariousratioswereextracteddatabase, namely PROWESS, compiledbyCMIE(Centrefor Monitoring Indian Economy). SPSS was used as the statistical package for multiple regressionanalysis. Sample firms were those that belong to the Biopharma sector, i.e., the firms that weremanufacturing their products either by incorporating biotechnology in their manufacturing processesor producing final products such as enzymes, antibiotics, antibodies, and proteins. Fifty firmsincorporated before 1995 were chosen based on systematic sampling for this study. However,thetotalstudyperiodhasbeenbifurcatedintotwoperiods, i.e., pre-patentperiod(1996-2005)andpost-patent period (2006-2018). To know about the financial performance of both periods.

Selectedprofitabilityratioswerecomputedtomeasurethefinancialperformanceofbiopharmaceuticalcompaniesinthe processpatentperiod, i.e.(1996to2005), andproductpatentperiod, i.e.(2006to2018).Thefollowingfigureshowsthevariouscomponentsoffinancialperformance:

Figure 1 Financial Performance and its Components



For the two dimensions mentioned above- profitability and growth, the following measures have beenused:

1. **Profitability:**Four accounting measures have been used to studybiopharmaceuticalcompanies' profitability. i.e., Net profit ratio(NPR), Return on Total Assets (ROTA), ReturnonCapitalEmployed(ROCE)andReturnonNetworth(RONW).

   a. **Net profit ratio:**Net profit ratioistheratioofnetprofitstocompany sales. This depicts the residual profit available for the shareholders after meeting all theexpensesandcosts.

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

V. NET PROFIT RATIO=PROFITAFTERTAXES/NETSALES

a. **Return on Total Assets: Return on Total Assets** is calculated by dividing the operatingincome after taxes by total assets. ROTA shows the productivity of average total assetstogenerateprofits.

VI. RETURNONTOTALASSETS=PROFITAFTERTAX/AVERAGETOTAL ASSETS

a. **Return on Capital Employed:**Return on capital employed measures the efficacy of thecapital employed in the firm to generate profits. ROCE is computed by dividing theearnings available for equity shareholders by the average capital employed in the firm.Capitalemployedrepresentsnetworth(sharecapitalplusretainedearningsminusaccumulatedlosses, if any)+ long-term liabilities. Average capital employed represents the average ofcapitalemployedatthebeginningandtheendofaparticularfinancialyear.

VII. RETURNONCAPITALEMPLOYED=PROFITAFTERTAX/AVERAGECAPITAL EMPLOYED

a. **Return on Net Worth:** The return on net worth measures how efficiently a firm can generateincomeusingshareholders'funds.Tocalculatethereturnonnetworth,earningsaftertaxare takenin the numerator, andaveragenetworthistakenin the denominatorforcalculatingtheratioofreturnonnet worth.

VIII. RETURNONNETWORTH=PROFITAFTERTAX/AVERAGENETWORTH

2. **Measuring Growth:**The literature on the relationship between financial performance and growthmeasures indicated mixed evidence. Czarnitzki *et al.* [23] stated that growth leads toenhanced profitability till the firm attains the optimum level, and after this level, the growthwill not be translated into profitability. The empirical studies by Kuntluru *et al. [25]* and Vijaya Kumar [26] elucidate a positive association between salesgrowth and financial performance. To measure the growth rate, three parameters, namelypercentsalesgrowth,percenttotalassetsgrowth, andpercentmarketcapitalizationgrowthhavebeenusedasourgrowthmeasures.

The Total assets growth: The total assets growthhasbeencomputed asfollows:

$$\text{Assetsgrowth}_t = \frac{\text{TotalAssets}_t - \text{TotalAssets}_{t-1}}{\text{TotalAssets}_{t-1}}$$

The Total sales growth: total sales growthhasbeencomputedasfollows:

$$\text{Salesgrowth}_t = \frac{\text{TotalSales}_t - \text{Total Sales}_{t-1}}{\text{TotalSales}_{t-1}}$$

The market capitalization growth: Themarket capitalization growthhasbeencomputed asfollows:

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

$$MarketCapitalizationgrowth_{t}=\frac{MarketCapitalization_{t}-MarketCapitalization_{t-1}}{MarketCapitalization_{t-1}}$$

In the abovementioned formula, t stands for the last year, and t-1 stands for the start year.**ComparativeAnalysisofdependentfactorsaffectingthe financialPerformanceofbiopharmacompaniesbetweenprocesspatentperiodandproductpatentPeriod**

Thesnapshotofvariousdependentfactorsoffinancialperformanceis describedin the previoussection.Tostatisticallyanalyzethesame,pairedsamplest-testhasbeenemployed.Table1.1comparesselecteddependentvariablesofthe financialperformanceofbiopharmaceuticalcompaniesinIndiaduringthe per-productandproductpatentperiods.

Table1.1representsthe empiricalresultsofpairedsamples*t*-testofthevariousdependentindicatorsoffinancialperformanceinpre- andproductpatentperiods.

Hypothesis 1 assumes that the Net profit ratio during the process patent period and productpatentperiodisnotsignificantlydifferentduringthe processpatentperiodandtheproductpatentperiod.Thefirstmeasuretoanalyzethefactorsaffectingthe financialperformanceofbiopharmacompanies between the process patent period and the product patent period has been the Net profit ratio. Table 1.1 reveals that, on average, the Net profit ratio increased from an averageof 2.1682 in the process patent period to 2.2948 during the product patent period, whichremainedinsignificantinstatisticaltermsata 5% significance level.Asthe probabilityvalueofthe t statisticwasinsignificantat a 5%significance level, ourhypothesis1wasrejected.Itshowsthatfirms' Net profit ratiohadnotsignificantlyincreasedintheproductpatentperiodcomparedtotheprocesspatentperiod, andthischangeisstatisticallyinsignificant.

On average, our second indicator return on total assets had been 1.6241 during the process patentperiod, whereas the same decreased to 1.5480 during the product patent period. The *t*-value isinsignificantinstatisticaltermsat5%orevenbetterlevelofsignificance.Itimpliesthatthe returnontotalassetsbetweenthetwoperiodshasbeenstatisticallyinsignificant.Asthe Pvalueisstatisticallyinsignificant, our null hypothesis, namely the Return on Total Assets during the process patent period, isnot significantly different from the Return on Total Assets during the product patent period isaccepted, meaning thereby that the decline in the ratio of return on total assets of firms between both theperiodswasnotsignificantlydifferent.

Tableno.1.1Pairedt-test

DependentVariables		**Mean**	**Std. Deviation**	**t-value**	**p-value**
Net profit ratio	1996-2005	2.1682	.54055	1.691	.097
	2006-2018	2.2948	.11838		
Returnontotalassets	1996-2005	1.6241	.20034	1.365	.179
	2006-2018	1.5480	.35892		
ReturnonCapital	1996-2005	1.6685	.28820	1.266	.212

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

Employed	2006-2018	1.5758	.49122		
ReturnonNetWorth	1996-2005	1.7364	.46469	.515	.609
	2006-2018	1.7855	.62174		
Sales Growth	1996-2005	.9819	.9075	3.312	.002**
	2006-2018	.6099	.6030		
Totalassets growth	1996-2005	.6010	.6401	1.171	.247
	2006-2018	.4912	.6877		
Marketcapitalizationg rowth	1996-2005	.5222	.6926	2.214	.032*
	2006-2018	.2867	.5054		

IX. SOURCE:COMPUTED

Hypothesis3assumesnosignificantdifferenceinReturnonCapitalEmployedduringpre- and product patent periods. The Table 1.1reveals that, on average, theReturnonCapitalEmployedofallthefirmsdecreasedfromanaverageof 1.6685timesintheprocesspatent period to 1.5758 times during the product patent period, which remained insignificant instatistical terms at a 5% level of significance. The null hypothesis has been accepted because the *t*-statistic is significant at a 5% level of significance. It shows that theReturn on Capital Employed offirms had not changed significantly during the process patent period and product patent period,meaningthat the declineinthe returnratio oncapitalemployedisnotstatisticallysignificant.

On average, our fourth indicator return on net worth had been 1.7364 during the process patentperiod, whereas the same increased to 1.7855 during the product patent period. The *t*-value isinsignificantat5%oran evenbettersignificance level.Itimpliesthat the returnonnetworthbetweenthetwo periods has been statistically insignificant. “As the P value is statistically insignificant, our nullhypothesis, namely, there is no significant difference in return on net worth during the process patentperiod and product patent period, is accepted, meaning thereby that there is an increase in the ratio of return on the networthoffirmsbetweenboththeperiodsisnotstatisticallysignificant.”

Hypothesis5assumesthatthereisnosignificantdifferenceinsales growthduringpre- andproductpatentperiods. Table1.1revealsthat, onaverage, thegrowthinsalesofall the firms decreased from an average of 0.9819 times in the process patent period to 0.6099 timesduring the product patent period, which remained significant in statistical terms at a 5% significance level.Thenullhypothesis, i.e., Nosignificantdivergenceisfoundfora Total assets growthduringthe processand productpatentperiods, hasbeenrejectedbecausethe*t*-statistic value is significant. It shows that there is a significant change in growth in sales of firmsduring the process patent period and product patent period, meaning that the decline insalesisstatisticallysignificant.During postproductpatentperiod, companiescould not usereverseengineering, whichaffectedtheirsales.

Onaverage, oursixthindicator total assets growthhadbeen0.6010duringtheprocesspatentperiod, whereas the same decreased to 0.4912 during the product patent period. The *t*-value isinsignificant at 5% or an even better significance level. It implies that total assets growth betweenthe two periods has been statistically insignificant. As the P value is statistically insignificant, our nullhypothesis, namely, thereisnosignificantdifferencein total assets growthduringthe processpatentperiod and product patent period, is accepted, meaning thereby that the Total sales growthduring the process patent period and the product patent period is not significantly varied. It isinterpretedthatthe declineinthe growth ratio intotalassetsisnotstatisticallysignificant.

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

Hypothesis 7 assumes that there is no significant difference in market capitalization growth duringpre-andproductpatentperiods.TheTable1.1revealsthat, onaverage, themarket capitalization growth of all the firms decreased from an average of 0.5222 times in the processpatentperiodto0.2867timesduringtheproductpatentperiod,whichremainedsignificantin statistical terms at a 5% level of significance. The null hypothesis, i.e., there is no considerabledifference in the market capitalization growth during process patent and product patent periods, has been rejected because the *t*-statistic remained significant in statistical terms5%significance level.Itshowsthatthereis a significantchangeinthe marketcapitalizationoffirmsduringthe processpatentperiodandproductpatentperiod,meaningthat the declinein market capitalization growth is statistically significant. In post product patent period, growth in the marketpriceofcompanieswasnotasmuchasinthe processpatentperiod.

X. CONCLUSION

In conclusion, this longitudinal study on the trends in financial performance and market capitalization of biopharmaceutical companies provides valuable insights into the dynamics of this critical sector. The findings reveal a multifaceted landscape characterized by consistent growth, evolving financial patterns, and shifting investor sentiments. Throughout the study, we observed substantial revenue growth within the biopharmaceutical companies, highlighting the industry's resilience and ability to capitalize on innovation and research advancements. Moreover, profitability metrics demonstrated a mix of successes and challenges, suggesting that while some companies thrived, others faced obstacles in maximizing their financial gains. Liquidity and solvency indicators played a crucial role in determining the financial health of the companies, impacting their ability to navigate economic uncertainties and pursue strategic initiatives. This emphasizes the importance of prudent financial management and risk mitigation strategies for long-term sustainability in the biopharmaceutical industry. As a reflection of investor sentiment and market valuation, market capitalization exhibited notable fluctuations over the study period. Financial performance metrics and factors such as regulatory approvals, pipeline prospects, and external market trends influenced investor perceptions. It underscores the significance of effective communication, transparency, and proactive engagement with investors to foster confidence and maintain market capitalization growth. The research also identified potential correlations between financial performance and market capitalization trends, further reinforcing the symbiotic relationship between financial stability and investor confidence. This highlights the critical role of financial data in shaping investor decisions and underscores the need for companies to prioritize financial transparency and accountability. Understanding its financial landscape becomes increasingly vital as the biopharmaceutical industry plays a pivotal role in healthcare advancements and addresses global health challenges. Investors, executives, policymakers, and stakeholders can leverage the insights from this study to make informed decisions, develop robust strategies, and navigate the complexities of this dynamic sector.

However, it is essential to acknowledge some limitations of the study. The data used in this research is historical and may not fully capture ongoing developments or unforeseen events that could impact financial performance and market capitalization. “Additionally, the study primarily focused on quantitative financial metrics, and further research could incorporate qualitative aspects to gain a comprehensive understanding of the industry.”In summary, the longitudinal study contributes to the body of knowledge on the biopharmaceutical sector by comprehensively analyzing financial performance and market capitalization trends. It offers a holistic view of the industry's dynamics and growth potential, guiding stakeholders toward making informed decisions in an

ISSN PRINT 2319 1775 Online 2320 7876

Research paper© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

ever-evolving and impactful domain. Continuous research and scrutiny of the biopharmaceutical industry's financial landscape will be essential to grasp emerging trends and ensure sustainable growth for both the industry and society at large.

XI. REFERENCES

[1]. United Nations, 2015. Transforming our world: The 2030 agenda for sustainable development. 2015. Available online: https://www.refworld.org/docid/57b6e3e44. hm

[2]. Pineiro-Chousa, ˜ J., Lopez-Cabarcos, ´ M.A., ´ Caby, J., Sevi ˇ ´c, A., 2021. The influence of investor sentiment on the green bond market. Technol. Forecast. Soc. Change 162, 120351. https://doi.org/10.1016/j.techfore.2020.120351.

[3]. Calabrese, A., Costa, R., Ghiron, N.L., Tiburzi, L., Pedersen, E.R.G., 2021. How sustainable-orientated service innovation strategies are contributing to the sustainable development goals. Technol. Forecast. Soc. Change 169, 120816. https://doi.org/10.1016/j.techfore.2021.120816.

[4]. World Economic Forum, 2021. The global risks report 2021. 16th edition. World Economic Forum. Available online: https://www.weforum.org/reports/the-globalrisks-report-2021.

[5]. Planetary Health Alliance, 2021. Accessed February 17, 2021. https://www.planetaryh ealthalliance.org.

[6]. Myers, S.S., 2017. Planetary health: protecting human health on a rapidly changing planet. Lancet North Am. Ed. 390 (10114), 2860–2868. https://doi.org/10.1016/ S0140-6736(17)32846-5.

[7]. Haines, A., Ebi, K., 2019. The imperative for climate action is to protect health. N. Engl. J. Med. 380, 263–273. https://www.nejm.org/doi/full/10.1056/nejmra1807873..

[8]. Bandh, S.A., Shafi, S., Peerzada, M., Rehman, T., Bashir, S., Wani, S.A., Dar, R., 2021. Multidimensional Analysis of global climate change: a review. Environ. Sci. Pollut. Res. 28, 24872–24888. https://doi.org/10.1007/s11356-021-13139-7

[9]. Pineiro-Chousa, ˜ J., Lopez-Cabarcos, ´ M.A., ´ Ribeiro-Soriano, D., 2020. Does investor attention influence water companies' stock returns? Technol. Forecast. Soc. Change 158, 120115. https://doi.org/10.1016/j.techfore.2020.120115

[10]. Faivre, N., Fritz, M., Freitas, T., de Boissezon, B., Vandewoestijne, S., 2017. Nature-Based Solutions in the EU: Innovating with nature to address social, economic, and environmental challenges. Environ. Res. 159, 509–518. https://doi.org/10.1016/j. envies.2017.08.032

[11]. Lo, Andrew W., and Richard T. Thakor, "Financing Medical Innovation." (2021).

[12]. Schumpeter, Joseph. "Creative destruction." Capitalism, socialism and democracy 825 (1942): 82-85.

[13]. Arrow, Kenneth J. "Uncertainty and the welfare economics of medical care." American Economic Review 53 (1963): 941–973.

[14]. Hall, Bronwyn H., and Josh Lerner. "The financing of R&D and innovation." In Handbook of the Economics of Innovation, vol. 1, pp. 609-639. North-Holland, 2010.

[15]. Kerr, William R., and Ramana Nanda. "Financing innovation." Annual Review of Financial Economics 7 (2015): 445-462.

[16]. Nanda, Ramana, and Matthew Rhodes-Kropf. "Financing entrepreneurial experimentation." Innovation Policy and the Economy 16, no. 1 (2016): 1-23.

[17]. Scannell, Jack W., Alex Blanckley, Helen Boldon, and Brian Warrington. "Diagnosing the decline in pharmaceutical R&D efficiency." Nature Reviews Drug Discovery 11, no. 3 (2012): 191-200

[18]. Thakor, Richard T., Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, and Andrew W. Lo. "Just how good an investment is the biopharmaceutical sector?" Nature Biotechnology 35, no. 12 (2017): 1149-1157

[19]. Brown, James R., Steven M. Fazzari, and Bruce C. Petersen. "Financing innovation and growth: Cash flow, external equity, and the 1990s R&D boom." The Journal of Finance 64, no. 1 (2009): 151-185.

[20]. Aghamolla, Cyrus, and Richard T. Thakor. "IPO peer effects." Journal of Financial Economics 144, no. 1 (2021): 206-226.

[21]. Myers, Stewart C., and Nicholas S. Majluf. "Corporate financing and investment decisions when firms have information that investors do not have." Journal of financial economics 13, no. 2 (1984): 187-221.

[22]. Liu, Tong. "Bargaining with Private Equity: Implications for Hospital Prices and Patient Welfare." Available at SSRN 3896410 (2021).

[23]. Tirole, Jean. The Theory of Corporate Finance. Princeton University Press (2006).

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 4, 2022

[24]. Czarnitzki, D., Etro, F. and Kraft, K. (2011), "Endogenous Market Structures and Innovation by Leaders",Working Paper, retrievedfrom http://www.unive.it/media/allegato/DIP/Economia/Working_papers/Working_papers_2011/WP_DSE_czarnitzki_etro_kraft_04_11.pdf, accessed on Sep 01, 2013.

[25]. Kuntluru, S., Muppani, V.R. and Khan, A.A. (2008), "Financial Performance of Foreign and Domestic Owned Companies in India," Journal of Asia Pacific Business, 9(1), pp.28-54.

[26]. Kumar A. (2008), "Biogeneric Manufacturing in India," Advances in Biopharmaceutical Technology in India. Biospectrum Asia; Jan 2008.